Elicio Therapeutics, Inc. - Common Stock — Flux de trésorerie (NASDAQ:ELTX) | MetaTrader

Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques

Trimestriel Annuel

Flux de trésorerie liés aux activités d'exploitation -52.64 M-38.39 M-32.69 M-37.07 M-36.95 M -38.48 M Flux de trésorerie liés aux activités d'investissement -382 K0-32 K-84 K-16 K — Flux de trésorerie liés aux activités de financement 107.17 M-60 K38.61 M42.32 M36.7 M 34.39 M Flux de trésorerie disponible -52.64 M-38.39 M-32.69 M-37.07 M-36.97 M -38.49 M

Nouvelles

Elicio Therapeutics: Hoping To Capitalize On Massive KRAS Hype, But Time Is Running Out

Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?

H.C. Wainwright relève l’objectif de cours d’Elicio Therapeutics à 17$

H.C. Wainwright raises Elicio Therapeutics price target to $17

Rodman & Renshaw initie la couverture d’Elicio Therapeutics avec une recommandation d’achat

Rodman & Renshaw initiates Elicio Therapeutics stock with buy rating

Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year?

Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why

Elicio reports antigen spreading in 87% of evaluated cancer patients

Elicio Therapeutics appoints Marc Wolfgang as chief technology officer

Elicio reports strong immune responses in phase 2 KRAS cancer vaccine trial

Elicio’s cancer therapy shows immune response across diverse HLA types